Who is affected? Most cases are identified in the context of assisted reproductive technology (ART) – in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). However, spontaneous conception can also be impacted, although the abnormality may go unnoticed until a very early miscarriage. Women undergoing fertility treatment are therefore the largest group in which zygote cleavage abnormalities are diagnosed.

Prevalence varies by population and laboratory techniques. Large IVF registries report cleavage abnormalities in approximately 10–20 % of fertilised oocytes, with severe arrest (< 2‑cell stage) seen in 5–8 % of cycles (ESHRE 2022; CDC ART Success Rates 2023). In natural conception, early embryonic loss (often related to cleavage problems) is estimated at 30–40 % of all conceptions, but the exact proportion attributable specifically to cleavage defects is uncertain because many losses occur before clinical detection.

Symptoms

Because the problem occurs at a microscopic stage, most patients experience no direct physical symptoms. The signs are usually indirect, discovered during fertility work‑up or after a pregnancy loss. Below is a comprehensive list of possible clinical cues:

• Repeated early pregnancy loss (before 8 weeks) – often the first indication that an embryo is failing to develop properly.
• Failure to achieve a clinical pregnancy after multiple IVF cycles despite good‑quality embryos at later stages.
• Low fertilisation rate in IVF/ICSI (e.g., < 30 % of oocytes becoming zygotes).
• Abnormal embryo morphology on microscopy – asymmetrical blastomeres, cytoplasmic fragments, or multinucleated cells observed on day 1–3.
• Irregular menstrual bleeding is not a direct symptom but may prompt evaluation if pregnancy is suspected.
• Pain or cramping may occur if a very early miscarriage happens, but this is a result of loss, not the cleavage defect itself.

Causes and Risk Factors

Cleavage abnormalities are multifactorial. The following mechanisms have been identified in research and clinical practice:

Genetic Factors

• Chromosomal aneuploidy – extra or missing chromosomes are the most common cause of early arrest (< 30 % of all embryos – Mayo Clinic, 2022).
• Mitochondrial DNA defects impair energy production needed for cell division.
• Single‑gene mutations in spindle‑assembly checkpoint proteins (e.g., BUB1B) can lead to multinucleation.

Maternal Factors

• Advanced maternal age (≥ 35 years) – higher aneuploidy rates.
• Ovarian stimulation protocols that produce very high oocyte yields may increase the proportion of immature oocytes.
• Endocrine disorders (e.g., uncontrolled diabetes, thyroid disease) that affect oocyte quality.

Paternal Factors

• Severe sperm DNA fragmentation or chromatin abnormalities (assessed by SCSA or TUNEL assays).
• Age‑related decline in sperm quality.

Laboratory & Technical Factors

• Suboptimal culture media pH or temperature.
• Mechanical stress during oocyte handling or intracytoplasmic sperm injection.
• Exposure to cryoprotectants without proper equilibration, leading to zona‑hardening.

Environmental & Lifestyle Factors

• Smoking, excessive alcohol, and recreational drug use – associated with increased DNA damage in gametes.
• Exposure to environmental toxins (pesticides, phthalates) that affect gamete integrity.
• Obesity (BMI > 30 kg/m²) – linked to altered oocyte metabolism.

Diagnosis

Because cleavage abnormalities are microscopic events, they are diagnosed through embryology laboratory techniques or, less frequently, by molecular testing of a product of conception after miscarriage.

Embryology Assessment (IVF/ICSI)

• Time‑lapse imaging (e.g., EmbryoScope) allows continuous observation of division timing, revealing asynchronous or arrested cleavage.
• Standard light microscopy on day 1–3 – embryologists grade embryos based on cell number, symmetry, and presence of fragments.
• Pre‑implantation genetic testing for aneuploidy (PGT‑A) – biopsies of 5‑cell embryos to detect chromosomal abnormalities that often cause arrest.

Genetic & Molecular Testing

• Chromosomal microarray (CMA) on trophectoderm cells (if the embryo reaches blastocyst).
• Next‑generation sequencing (NGS) of embryonic DNA for specific gene defects.
• Mitochondrial DNA copy‑number analysis – high mtDNA burden may predict poor cleavage.

Clinical Evaluation after Pregnancy Loss

• Chromosomal analysis of the lost embryo (karyotyping or microarray) can confirm aneuploidy‑related cleavage failure.
• Maternal blood work – thyroid panel, glucose tolerance test, and hormone levels to rule out systemic contributors.

Treatment Options

Therapeutic strategies aim to improve the quality of the gametes, optimise laboratory conditions, or select the healthiest embryos for transfer.

Optimising Gamete Quality

• Pre‑conception counseling – smoking cessation, alcohol moderation, weight optimisation (BMI 18‑25 kg/m²).
• Antioxidant supplementation (e.g., coenzyme Q10, melatonin) has shown modest improvement in oocyte mitochondrial function (Cleveland Clinic, 2021).
• Hormonal optimisation – adequate luteinising hormone (LH) surge, controlled ovarian hyperstimulation (COH) protocols tailored to age and ovarian reserve.
• Sperm selection techniques – density gradient centrifugation, hyaluronic‑binding assay, or microfluidic devices to reduce DNA fragmentation.

Laboratory Interventions

• Improved culture media containing essential amino acids and antioxidants (e.g., G5™ medium) reduces oxidative stress.
• Time‑lapse monitoring to identify the most competent embryos for transfer, bypassing those with abnormal cleavage patterns.
• Sequential embryo transfer – transferring a day‑5 blastocyst after confirming normal cleavage reduces the risk of transferring a compromised embryo.
• PGT‑A – discarding aneuploid embryos before transfer improves live‑birth rates by 10‑15 % in older women (NIH, 2022).

Medical Therapies

• Growth‑factor supplementation (e.g., granulocyte‑macrophage colony‑stimulating factor) added to culture has experimental support but is not yet standard of care.
• Low‑dose aspirin or heparin – may improve uterine perfusion in women with antiphospholipid syndrome, indirectly supporting implantation of a healthy embryo.

Alternative Reproductive Options

• Donor oocytes – especially for women with repeated cleavage failure linked to poor oocyte quality.
• Adoption or surrogacy – viable pathways when biological options are exhausted.

Living with Zygote Cleavage Abnormalities

Managing this condition involves both medical follow‑up and emotional self‑care.

• Keep a detailed fertility diary – record cycle dates, medication doses, and any symptoms of early loss.
• Attend regular follow‑up appointments with your reproductive endocrinologist to review embryo grading reports.
• Seek counseling or support groups – repeated IVF failures can be emotionally taxing; professional counseling improves coping (American Society for Reproductive Medicine, 2023).
• Maintain a healthy lifestyle – balanced diet rich in folate, omega‑3 fatty acids, and low in trans‑fats supports gamete health.
• Mind‑body techniques – yoga, meditation, or acupuncture have been shown to lower stress hormones that may impair implantation.

Prevention

While not all cleavage abnormalities are preventable, risk can be lowered by addressing modifiable factors:

1. Quit smoking and avoid second‑hand smoke.
2. Limit alcohol to ≤ 1 drink per day (women) or abstain during fertility treatment.
3. Achieve a healthy body weight; aim for a BMI between 18‑25 kg/m² before starting IVF.
4. Screen and treat chronic conditions (diabetes, thyroid disease, hypertension) before conception.
5. Choose an IVF laboratory with documented quality‑control metrics (e.g., low embryo arrest rates, use of time‑lapse incubators).
6. Consider antioxidant supplementation (co‑Q10 200 mg daily) for at least 2 months before ovarian stimulation – discussed with your physician.

Complications

If cleavage abnormalities are not recognised and addressed, the following complications may arise:

• Repeated early miscarriages – emotional distress, potential for cervical insufficiency after multiple dilations.
• Reduced cumulative live‑birth rate – leading to prolonged infertility and increased cost of treatment.
• Psychological sequelae – depression, anxiety, and relationship strain (estimated prevalence of depression in infertility patients: 40 % – WHO, 2021).
• Potential for invasive procedures – such as repeat IVF cycles, which carry risks of ovarian hyperstimulation syndrome (OHSS) and ectopic pregnancy.

When to Seek Emergency Care

For any non‑emergency concerns—such as abnormal ultrasound findings, recurrent implantation failure, or emotional distress—contact your fertility specialist promptly.

**References**

1. European Society of Human Reproduction and Embryology (ESHRE) Embryology Guidelines, 2022.
2. Centers for Disease Control and Prevention (CDC), Assisted Reproductive Technology Success Rates, 2023.
3. Mayo Clinic. “Chromosomal abnormalities in embryos.” Updated 2022.
4. National Institutes of Health (NIH). “Preimplantation Genetic Testing Improves Live‑Birth Rates.” 2022.
5. Cleveland Clinic. “Antioxidants and Female Fertility.” 2021.
6. American Society for Reproductive Medicine. “Psychological Impact of Infertility.” 2023.
7. World Health Organization. “Depression and Infertility.” 2021.